Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Healthy Adults
NCT07425821Phase 1Active, not recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Marburg virus disease (MVD) comparing rVSV∆G-MARV-GP with Placebo/Diluent (2 arms). Primary endpoints: Safety and tolerability: solicited reactogenicity at 14 days, Safety and tolerability: unsolicited reactogenicity at 28 days and 1 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
rVSVΔG-MARV (Angola) GP
03
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT07425821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425821.